USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
10 Oct 2022 | 02:45 PM GMT

Masterclass: DTx Reimbursement in the US: Government-sponsored plans (Medicaid and Medicare)

Anchored by:

Mike Pace
Founder & CEO
PALMHEALTHCO

Participants:

Mike Pace Founder & CEOPalmHealthCo
Mike Pace
Founder & CEOPalmHealthCo
Ameya Phadke Senior Director, Non Pharma SolutionsChiesi Group
Ameya Phadke
Senior Director, Non Pharma SolutionsChiesi Group
Brendan Staunton CEOAmara Therapeutics
Brendan Staunton
CEOAmara Therapeutics
Emma Carr Co-Founder and Chief Scientific OfficerAmara Therapeutics
Emma Carr
Co-Founder and Chief Scientific OfficerAmara Therapeutics
Gurdeep Sareen Regional Director of PharmacyOptum,Verywell
Gurdeep Sareen
Regional Director of PharmacyOptum,Verywell
Kennetth Joseph Gamify PharmacistAkili Interactive Labs
Kennetth Joseph
Gamify PharmacistAkili Interactive Labs
Leonardo Angelone Deputy DirectorThe National Institutes on Drug Abuse
Leonardo Angelone
Deputy DirectorThe National Institutes on Drug Abuse
Richard Bunney DirectorDeviceology
Richard Bunney
DirectorDeviceology
Saranya Ramakrishnan Director of Healthcare StrategyAggregate Insights
Saranya Ramakrishnan
Director of Healthcare StrategyAggregate Insights
Simon Bock Market Access ManagerTiefenbacher Pharmaceuticals
Simon Bock
Market Access ManagerTiefenbacher Pharmaceuticals

About this Meeting

Are you a digital therapeutics (DTx) company seeking reimbursement in the US market? How can you leverage Government-sponsored plans to get paid for your product?    

While we have seen a surge of DTx companies approaching private payers for DTx reimbursement, Medicare and Medicaid populations bring different sets of challenges and opportunities. Health improvement needs in these populations are substantial and these segments are major business opportunities for players in the DTx industry, accounting for almost half the US market. Join this masterclass led by the biopharma and DTx reimbursement expert Mike Pace to learn more about:  

  • When is targeting Medicare and/or Medicaid a good option for digital health companies seeking reimbursement? Which market segments are opportunistic under what conditions? 
  • How to approach Medicaid and Medicare decision makers and be seen as a trusted advisor? What specific requirements and considerations do you need to know about (e.g. state and federal policies, language and reading level requirements, population representation in clinical trials, state political agendas, etc.)? 
  • What type of access negotiations and reimbursement contracts are best suited for Medicaid and Medicare payers? 
  • Examples in the real world such as the inclusion of Pear’s products on the MassHealth non-drug list summary in 2021. What are the learnings from these kinds of examples?